Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Aldeyra Therapeutics
Biotech
Aldeyra’s dry eye drug suffers second FDA rejection
With a trial set to read out this quarter, the biotech is aiming to bounce back and resubmit its application in mid-2025.
Nick Paul Taylor
Apr 3, 2025 8:46am
Aldeyra preps for FDA refiling as dry eye drug hits ph. 3 goal
Aug 8, 2024 10:48am
Milestone resubmits NDA, Aldeyra readies 2nd chance filing
Mar 28, 2024 10:40am
ADC Tx, Aldeyra leave programs behind in 2023
Jan 4, 2024 10:05am
With FDA rejection for eye drug, Aldeyra plans speedy new trial
Nov 28, 2023 4:30am
Aldeyra forewarns potential FDA rejection for dry eye med
Oct 16, 2023 2:49pm
